Platinum Therapy May Up Survival in Pancreatic Cancer With DNA Repair Defects
TUESDAY, May 26, 2020 -- For patients with advanced-stage pancreatic ductal adenocarcinoma (PDAC), those with homologous recombination deficiency (HRD) have improved survival with first-line (1L) platinum treatment, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2020 Category: Pharmaceuticals Source Type: news
Why pancreatic ductal adenocarcinoma is so lethal
(Cold Spring Harbor Laboratory) Pancreatic ductal carcinoma is a fast growing and invasive cancer, and now scientists understand the molecular dance that makes it so deadly. CSHL researchers discovered factors that allow a pancreatic cell to lose its identity, turn into an aggressive cancer cell, and recruit surrounding cells to help it invade more effectively. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2020 Category: Cancer & Oncology Source Type: news
Esophageal, Gastric Adenocarcinomas After H. pylori Infection Esophageal, Gastric Adenocarcinomas After H. pylori Infection
Does treatment and eradication of H pylori reduce the risk of future esophageal and proximal gastric cancer?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Professionals Analyze Pathology Following lung Lobectomies for Adenocarcinoma
Researchers examined the pathology of early-phase COVID-19 pneumonia in two older patients who were admitted to the hospital for adenocarcinoma procedures, but did not exhibit COVID-19 symptoms at the time of these procedures. (Source: CancerNetwork)
Source: CancerNetwork - April 14, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Cysteine depletion induces pancreatic tumor ferroptosis in mice
Ferroptosis is a form of cell death that results from the catastrophic accumulation of lipid reactive oxygen species (ROS). Oncogenic signaling elevates lipid ROS production in many tumor types and is counteracted by metabolites that are derived from the amino acid cysteine. In this work, we show that the import of oxidized cysteine (cystine) via system xC– is a critical dependency of pancreatic ductal adenocarcinoma (PDAC), which is a leading cause of cancer mortality. PDAC cells used cysteine to synthesize glutathione and coenzyme A, which, together, down-regulated ferroptosis. Studying genetically engineered mice,...
Source: ScienceNOW - April 1, 2020 Category: Science Authors: Badgley, M. A., Kremer, D. M., Maurer, H. C., DelGiorno, K. E., Lee, H.-J., Purohit, V., Sagalovskiy, I. R., Ma, A., Kapilian, J., Firl, C. E. M., Decker, A. R., Sastra, S. A., Palermo, C. F., Andrade, L. R., Sajjakulnukit, P., Zhang, L., Tolstyka, Z. P., Tags: Cell Biology, Medicine, Diseases reports Source Type: news
10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer
MONDAY, March 23, 2020 -- For men with intermediate- and high-risk prostate adenocarcinoma, 10-year outcomes are similar with conventionally fractionated intensity-modulated radiation therapy (C-IMRT) or moderate hypofractionated IMRT (H-IMRT),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2020 Category: Pharmaceuticals Source Type: news
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[1] Cu...
Source: Johnson and Johnson - March 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Pancreatic Cancer Patients May Harbor Treatable Germline Mutations Pancreatic Cancer Patients May Harbor Treatable Germline Mutations
Germline mutations commonly found in individuals with pancreatic ductal adenocarcinoma (PDAC) may be treatable and should be identified as soon as possible, a comprehensive review suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 3, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis
Non–small cell lung cancer (NSCLC) is often characterized by mutually exclusive mutations in the epidermal growth factor receptor (EGFR) or the guanosine triphosphatase KRAS. We hypothesized that blocking EGFR palmitoylation, previously shown to inhibit EGFR activity, might alter downstream signaling in the KRAS-mutant setting. Here, we found that blocking EGFR palmitoylation, by either knocking down the palmitoyltransferase DHHC20 or expressing a palmitoylation-resistant EGFR mutant, reduced activation of the kinase PI3K, the abundance of the transcription factor MYC, and the proliferation of cells in culture, as we...
Source: Signal Transduction Knowledge Environment - March 2, 2020 Category: Science Authors: Kharbanda, A., Walter, D. M., Gudiel, A. A., Schek, N., Feldser, D. M., Witze, E. S. Tags: STKE Research Articles Source Type: news
HPV Biomarkers Linked to Improved Survival With Esophageal Dysplasia, Adenocarcinoma HPV Biomarkers Linked to Improved Survival With Esophageal Dysplasia, Adenocarcinoma
Human papillomavirus (HPV) positivity and HPV biomarkers are associated with improved survival in adults with Barrett high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC), according to a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 21, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
When a Promising Trial Fails, It Can Feel Personal When a Promising Trial Fails, It Can Feel Personal
Dr Mark Lewis shares how even with disappointing trial results, he remains hopeful that continuing research will craft a better present and future for our patients with pancreatic adenocarcinoma.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Overall survival in patients with lung adenocarcinoma harboring 'niche' mutations
(Impact Journals LLC) Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.The multivariable analysis showed that:Niche mutations had higher mortality than EGFR mutationsKRAS mutations had higher mortality than EGFR mutations, andNiche mutations presented similar mortality to KRAS mutations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 4, 2020 Category: Cancer & Oncology Source Type: news
Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma
This case of severe grade V thrombocytopenia caused by nivolumab highlights the need for clinicians to be aware of this potential adverse effect of immune-checkpoint inhibitors.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) (Source: World Pharma News)
Source: World Pharma News - December 31, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma
FDA approved olaparib (LYNPARZA ®, AstraZeneca) for maintenance treatment of patients with gBRCAm metastatic pancreatic adenocarcinoma, as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 30, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
